Publications by authors named "Sandy Srinivas"

100Publications

Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.

Urol Oncol 2020 Jun 24. Epub 2020 Jun 24.

Department of Urology, Stanford University Medical Center, Stanford, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.05.009DOI Listing
June 2020

Prostate Cancer Brain Metastases: A Single-Institution Experience.

World Neurosurg 2020 06 5;138:e445-e449. Epub 2020 Mar 5.

Department of Neurosurgery, Stanford University Medical Center, Stanford, California, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2020.02.152DOI Listing
June 2020

Application of pharmacoeconomics to formulary management in a health system setting.

Am J Health Syst Pharm 2019 Feb;76(6):381-386

Stanford University, Department of Medicine-Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajhp/zxy010DOI Listing
February 2019

Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.

Am Soc Clin Oncol Educ Book 2018 May;38:342-353

From the Stanford University School of Medicine/Stanford Cancer Center, Stanford, CA; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medicine, Division of Oncology, Stanford University School of Medicine/Stanford Cancer Center, Stanford, CA; Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201193DOI Listing
May 2018

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease.

Res Rep Urol 2018 26;10:7-16. Epub 2018 Jan 26.

Department of Oncology, Stanford University School of Medicine/Stanford Cancer Center, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/RRU.S125635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790095PMC
January 2018

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

J Clin Oncol 2017 11 30;35(31):3525-3528. Epub 2017 Aug 30.

Torgrim Tandstad, St Olavs University Hospital, Trondheim, Norway; Christian K. Kollmannsberger, University of British Columbia, Vancouver, British Columbia, Canada; Bruce J. Roth, Washington University School of Medicine, St Louis, MO; Claudio Jeldres, Sherbrooke University, Sherbrooke, Quebec, Canada; Silke Gillessen, Kantonsspital, St Gallen, Switzerland; Karim Fizazi, University of Paris Sud, Paris, France; Siamak Daneshmand, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA; William T. Lowrance, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Nasser H. Hanna, Indiana University School of Medicine, Indianapolis, IN; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Darren R. Feldman, Memorial Sloan Kettering Cancer Center and Weill Medical Cornell Medical College, New York, NY; Thomas Powles, Barts Cancer Institute, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; Mark A. Lewis, Intermountain Health, Salt Lake City, UT; Peter Scott Grimison, University of Sydney, Sydney, New South Wales, Australia; Douglas Bank, Testicular Cancer Resource Center, Riverwoods, IL; Christopher Porter, Virginia Mason Medical Center, Seattle, WA; Peter Albers, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; Maria De Santis, Cancer Research Center, University of Warwick, Coventry, United Kingdom; Sandy Srinivas, Stanford University School of Medicine, Stanford, CA; George J. Bosl, Memorial Sloan Kettering Cancer Center, New York, NY; and Craig R. Nichols, Precision Genomics Cancer Research Clinic, Intermountain Health, Salt Lake City, UT; Testicular Cancer Commons, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.4723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791831PMC
November 2017

Recommendations for the Management of Rare Kidney Cancers.

Eur Urol 2017 12 16;72(6):974-983. Epub 2017 Jul 16.

Division of Surgical Oncology, Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.06.040DOI Listing
December 2017

Consolidative Radiotherapy in Metastatic Urothelial Cancer.

Clin Genitourin Cancer 2017 12 12;15(6):685-688. Epub 2017 Apr 12.

Division of Oncology, Stanford Hospital, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.04.007DOI Listing
December 2017

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol 2017 10 14;72(4):557-564. Epub 2017 Apr 14.

Department of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.03.046DOI Listing
October 2017

Incorporating VEGF-targeted therapy in advanced urothelial cancer.

Ther Adv Med Oncol 2017 Jan 16;9(1):33-45. Epub 2016 Sep 16.

Division of Medical Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834016667179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298449PMC
January 2017

The effect of information on preferences for treatments of metastatic renal cell carcinoma.

Curr Med Res Opin 2016 11 11;32(11):1827-1838. Epub 2016 Aug 11.

d Pfizer , Sollentuna , Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2016.1211521DOI Listing
November 2016

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

J Clin Oncol 2016 Oct;34(30):3655-3663

Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Sabina Signoretti, and Toni K. Choueiri, Dana-Farber Cancer Institute; Wanling Xie, Rana R. McKay, Mark A. Preston, Eunyoung Cho, Sabina Signoretti, and Toni K. Choueiri, Brigham and Women's Hospital; Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Eunyoung Cho, David F. McDermott, Sabina Signoretti, and Toni K. Choueiri, Harvard Medical School; Mark A. Preston and Kathryn M. Wilson, Harvard School of Public Health; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Laurence Albiges, Gustave Roussy, Université Paris-Saclay, Villejuif, France; A. Ari Hakimi, Emily C. Zabor, Anders J. Skanderup, and Helena Furberg, Memorial Sloan Kettering Cancer Center, New York; Ronit Simantov and Xun Lin, Pfizer Oncology, New York, NY; Jae-Lyun Lee, University of Ulsan College of Medicine, Asan; Sun-Young Rha, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Sandy Srinivas, Stanford Cancer Institute, Stanford; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Georg A. Bjarnason, Sunnybrook Odette Cancer Center, Toronto; Scott Ernst, London Health Sciences Center, London, Ontario; Lori A. Wood, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia; Daniel Y.C. Heng, Tom Baker Cancer Center; University of Calgary, Calgary, Alberta, Canada; Ulka N. Vaishamayan, Karmanos Cancer Center, Detroit, MI; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Takeshi Yuasa, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Aristotelis Bamias, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; and Eunyoung Cho, The Warren Alpert Medical School of Brown University; Brown University School of Public Health, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065111PMC
October 2016

Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.

PLoS One 2016 28;11(4):e0153321. Epub 2016 Apr 28.

Department of Radiology, Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0153321PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849767PMC
February 2017

Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?

Eur Urol 2016 08 2;70(2):227-30. Epub 2016 Mar 2.

Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838160021
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2016.02.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927398PMC
August 2016

Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.

Nat Rev Urol 2016 Jan 8;13(1):47-60. Epub 2015 Dec 8.

Division of Endocrinology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305-5103, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrurol.2015.254
Publisher Site
http://dx.doi.org/10.1038/nrurol.2015.254DOI Listing
January 2016

Second-line therapies in metastatic urothelial carcinoma.

Hematol Oncol Clin North Am 2015 Apr 28;29(2):341-59, x. Epub 2015 Jan 28.

Department of Medicine, Stanford University School of Medicine, Blake Wilbur Drive, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.10.007DOI Listing
April 2015

The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.

JACC Heart Fail 2013 Feb 4;1(1):72-8. Epub 2013 Feb 4.

Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchf.2012.09.001DOI Listing
February 2013

Reply: To PMID 24529583.

Urology 2014 Apr 12;83(4):779-80. Epub 2014 Feb 12.

Department of Urology, University of California, Los Angeles School of Medicine, Los Angeles, CA; Department of Health Services, University of California, Los Angeles School of Medicine, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2013.10.077DOI Listing
April 2014

Utilization of renal mass biopsy in patients with renal cell carcinoma.

Urology 2014 Apr 12;83(4):774-9. Epub 2014 Feb 12.

Department of Urology, University of California, Los Angeles School of Medicine, Los Angeles, CA; Department of Health Services, University of California, Los Angeles School of Medicine, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2013.10.073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972335PMC
April 2014

Prostate cancer, version 1.2014.

J Natl Compr Canc Netw 2013 Dec;11(12):1471-9

From 1Roswell Park Cancer Institute; 2Dana-Farber/Brigham and Women's Cancer Center; 3Duke Cancer Institute; 4The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 5Huntsman Cancer Institute at the University of Utah; 6Memorial Sloan-Kettering Cancer Center; 7Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 8Prostate Health Education Network; 9University of Washington/Seattle Cancer Care Alliance; 10Fox Chase Cancer Center; 11City of Hope Comprehensive Cancer Center; 12Massachusetts General Hospital Cancer Center; 13Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 14Vanderbilt-Ingram Cancer Center; 15University of Michigan Comprehensive Cancer Center; 16Moffitt Cancer Center; 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The University of Texas MD Anderson Cancer Center; 20Patient Advocate; 21Stanford Cancer Institute; 22Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and 24National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0174DOI Listing
December 2013

Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.

Cancer Immunol Immunother 2013 Sep 23;62(9):1511-20. Epub 2013 Jul 23.

Oxford BioMedica (UK) Ltd., The Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-013-1457-zDOI Listing
September 2013

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer.

Invest New Drugs 2013 Aug 24;31(4):1044-50. Epub 2013 Feb 24.

Department of Solid Tumor Oncology, Cleveland Clinic, Taussig Cancer Institute, 9500 Euclid Ave R35, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9940-0DOI Listing
August 2013

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

Clin Genitourin Cancer 2013 Jun 24;11(2):100-6. Epub 2013 Jan 24.

Stanford Cancer Institute, Division of Oncology, Stanford School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2012.12.002DOI Listing
June 2013

Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillance.

Onkologie 2012 24;35(10):588-91. Epub 2012 Sep 24.

Division of Medical Oncology, Stanford University, CA 94305, USA.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/342695
Publisher Site
http://dx.doi.org/10.1159/000342695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364670PMC
March 2013

Toxicities of targeted agents in advanced renal cell carcinoma.

Curr Clin Pharmacol 2011 Aug;6(3):181-8

Stanford University, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157488411797189442DOI Listing
August 2011

Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).

Urol Oncol 2013 Apr 25;31(3):379-85. Epub 2011 Feb 25.

Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2011.01.005DOI Listing
April 2013

Pyoderma gangrenosum with the use of sunitinib.

J Clin Oncol 2011 Apr 10;29(10):e266-7. Epub 2011 Jan 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.32.6165DOI Listing
April 2011

The bevacizumab experience in advanced renal cell carcinoma.

Onco Targets Ther 2010 Oct 5;3:179-89. Epub 2010 Oct 5.

Division of Oncology, Stanford University School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962304PMC
http://dx.doi.org/10.2147/ott.s8157DOI Listing
October 2010

Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.

Dermatoendocrinol 2009 Jan;1(1):7-11

Department of Medicine; Divisions of Endocrinology; Stanford University School of Medicine; Stanford, California USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715203PMC
http://dx.doi.org/10.4161/derm.1.1.7106DOI Listing
January 2009

NCCN Task Force Report: Bone Health in Cancer Care.

J Natl Compr Canc Netw 2009 Jun;7 Suppl 3:S1-32; quiz S33-5

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047404PMC
http://dx.doi.org/10.6004/jnccn.2009.0076DOI Listing
June 2009

A phase II trial of calcitriol and naproxen in recurrent prostate cancer.

Anticancer Res 2009 Sep;29(9):3605-10

Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
September 2009

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.

Chemotherapy 2009 27;55(5):321-6. Epub 2009 Jul 27.

Division of Oncology, Stanford University School of Medicine, Stanford, California 94305-1205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000230695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814022PMC
December 2009

Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.

Cancer Invest 2009 Oct;27(8):851-6

Stanford University School of Medicine, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900902744528DOI Listing
October 2009

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

Nat Rev Urol 2009 Jun;6(6):338-43

Division of Oncology, Stanford University Medical Center, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2009.84DOI Listing
June 2009

The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.

Am J Clin Oncol 2008 Oct;31(5):417-23

Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e318168ef47DOI Listing
October 2008

Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.

Onkologie 2008 Sep 12;31(8-9):432-3. Epub 2008 Aug 12.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000144179DOI Listing
September 2008

Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.

Cancer 2008 Jul;113(1):72-7

Department of Genitourinary Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23519DOI Listing
July 2008

Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Expert Rev Anticancer Ther 2007 Dec;7(12):1749-61

Fellow, Medical Oncology, Stanford University School of Medicine, Division of Medical Oncology, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.7.12.1749DOI Listing
December 2007

Acute pancreatitis associated with sorafenib.

South Med J 2007 Sep;100(9):909-11

Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SMJ.0b013e31813c695dDOI Listing
September 2007